| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Estrogen | 106 | 2023 | 428 | 5.260 |
Why?
|
| Estrogen Receptor alpha | 41 | 2025 | 159 | 5.160 |
Why?
|
| Breast Neoplasms | 80 | 2026 | 3272 | 2.970 |
Why?
|
| Drug Resistance, Neoplasm | 14 | 2026 | 665 | 2.210 |
Why?
|
| Receptors, Progesterone | 38 | 2017 | 207 | 1.640 |
Why?
|
| Pyrrolidines | 5 | 2024 | 61 | 1.160 |
Why?
|
| Selective Estrogen Receptor Modulators | 12 | 2022 | 34 | 1.150 |
Why?
|
| Estrogens | 17 | 2020 | 202 | 1.140 |
Why?
|
| Tetrahydronaphthalenes | 3 | 2024 | 16 | 1.060 |
Why?
|
| Estrogen Receptor beta | 9 | 2013 | 26 | 1.010 |
Why?
|
| Estradiol | 39 | 2020 | 268 | 0.970 |
Why?
|
| Ligands | 23 | 2022 | 486 | 0.910 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2025 | 33 | 0.890 |
Why?
|
| MCF-7 Cells | 15 | 2025 | 123 | 0.880 |
Why?
|
| Cell Line, Tumor | 25 | 2026 | 2892 | 0.860 |
Why?
|
| Aromatase Inhibitors | 1 | 2024 | 29 | 0.830 |
Why?
|
| Tamoxifen | 21 | 2022 | 176 | 0.810 |
Why?
|
| Estrogen Antagonists | 17 | 2022 | 47 | 0.790 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 7 | 2017 | 126 | 0.770 |
Why?
|
| Esters | 1 | 2023 | 31 | 0.750 |
Why?
|
| Organophosphonates | 1 | 2023 | 46 | 0.750 |
Why?
|
| Endocrinology | 2 | 2013 | 51 | 0.750 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2026 | 159 | 0.720 |
Why?
|
| Estrogen Receptor Antagonists | 2 | 2019 | 2 | 0.720 |
Why?
|
| Binding Sites | 22 | 2018 | 1159 | 0.680 |
Why?
|
| Protein Binding | 18 | 2021 | 1554 | 0.670 |
Why?
|
| Transcription Factors | 11 | 2022 | 1717 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 40 | 1993 | 1416 | 0.620 |
Why?
|
| Animals | 85 | 2026 | 28904 | 0.590 |
Why?
|
| Humans | 153 | 2026 | 98088 | 0.560 |
Why?
|
| Signal Transduction | 16 | 2022 | 3620 | 0.550 |
Why?
|
| Models, Molecular | 17 | 2021 | 1392 | 0.540 |
Why?
|
| Tea | 2 | 2008 | 19 | 0.540 |
Why?
|
| Cell Nucleus | 25 | 2014 | 615 | 0.530 |
Why?
|
| Female | 114 | 2026 | 51541 | 0.520 |
Why?
|
| Protein Conformation | 10 | 2021 | 924 | 0.520 |
Why?
|
| Stilbenes | 3 | 2020 | 26 | 0.520 |
Why?
|
| Mice | 31 | 2026 | 12706 | 0.520 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2019 | 130 | 0.510 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2013 | 35 | 0.510 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2025 | 557 | 0.510 |
Why?
|
| Mutation, Missense | 2 | 2016 | 302 | 0.500 |
Why?
|
| DNA | 17 | 2022 | 1274 | 0.480 |
Why?
|
| Chromatin | 2 | 2016 | 454 | 0.470 |
Why?
|
| Cell Proliferation | 8 | 2025 | 1790 | 0.460 |
Why?
|
| Mutation | 19 | 2025 | 4396 | 0.450 |
Why?
|
| Receptors, Steroid | 4 | 2013 | 43 | 0.450 |
Why?
|
| Uterus | 21 | 2018 | 232 | 0.430 |
Why?
|
| Neoplasm Proteins | 5 | 2013 | 551 | 0.430 |
Why?
|
| Crystallography, X-Ray | 11 | 2021 | 530 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2025 | 1394 | 0.420 |
Why?
|
| Chemistry, Organic | 1 | 2013 | 2 | 0.400 |
Why?
|
| Genitalia | 1 | 2013 | 18 | 0.400 |
Why?
|
| Urogenital Neoplasms | 1 | 2013 | 25 | 0.400 |
Why?
|
| Pyrazoles | 4 | 2009 | 160 | 0.390 |
Why?
|
| Protein Structure, Tertiary | 10 | 2014 | 731 | 0.380 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 2573 | 0.380 |
Why?
|
| Promoter Regions, Genetic | 10 | 2018 | 977 | 0.380 |
Why?
|
| Trans-Activators | 2 | 2013 | 447 | 0.360 |
Why?
|
| Transcriptional Activation | 5 | 2017 | 293 | 0.350 |
Why?
|
| Carrier Proteins | 13 | 2007 | 667 | 0.350 |
Why?
|
| NF-kappa B | 4 | 2022 | 423 | 0.340 |
Why?
|
| Receptors, Androgen | 6 | 2018 | 125 | 0.340 |
Why?
|
| DNA-Binding Proteins | 8 | 2003 | 1255 | 0.340 |
Why?
|
| Lactate dehydrogenase-elevating virus | 1 | 2011 | 6 | 0.330 |
Why?
|
| Transcription, Genetic | 12 | 2020 | 1133 | 0.330 |
Why?
|
| Structure-Activity Relationship | 9 | 2020 | 425 | 0.330 |
Why?
|
| Immunohistochemistry | 20 | 2014 | 1815 | 0.330 |
Why?
|
| Peptides | 5 | 2019 | 669 | 0.320 |
Why?
|
| Gene Knock-In Techniques | 2 | 2009 | 31 | 0.310 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 2373 | 0.310 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 375 | 0.300 |
Why?
|
| Infertility, Male | 1 | 2009 | 29 | 0.290 |
Why?
|
| Protein Structure, Secondary | 7 | 2018 | 340 | 0.280 |
Why?
|
| Biomedical Research | 1 | 2013 | 471 | 0.280 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2008 | 3 | 0.280 |
Why?
|
| Catechin | 1 | 2008 | 23 | 0.280 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2008 | 3 | 0.280 |
Why?
|
| Genome, Human | 1 | 2013 | 832 | 0.270 |
Why?
|
| Pyrimidines | 2 | 2008 | 413 | 0.270 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 91 | 0.270 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1850 | 0.270 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 16 | 0.270 |
Why?
|
| Cinnamates | 2 | 2016 | 8 | 0.260 |
Why?
|
| Gene Expression Regulation | 15 | 2016 | 2023 | 0.260 |
Why?
|
| Pyridines | 4 | 2024 | 318 | 0.250 |
Why?
|
| Molecular Sequence Data | 14 | 2012 | 2896 | 0.250 |
Why?
|
| Gene Expression | 6 | 2015 | 1320 | 0.250 |
Why?
|
| Piperazines | 3 | 2024 | 306 | 0.250 |
Why?
|
| Cell Line | 21 | 2021 | 2483 | 0.250 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2005 | 557 | 0.240 |
Why?
|
| Ceramides | 1 | 2026 | 36 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 356 | 0.240 |
Why?
|
| Molecular Structure | 8 | 2020 | 305 | 0.240 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2026 | 98 | 0.230 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 337 | 0.230 |
Why?
|
| Endometrium | 9 | 1989 | 51 | 0.230 |
Why?
|
| Phenols | 3 | 2018 | 51 | 0.230 |
Why?
|
| Indoles | 3 | 2018 | 334 | 0.230 |
Why?
|
| Diethylstilbestrol | 5 | 2008 | 121 | 0.220 |
Why?
|
| Mammary Glands, Animal | 3 | 2013 | 82 | 0.220 |
Why?
|
| Amino Acid Sequence | 11 | 2018 | 2006 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1536 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 88 | 0.210 |
Why?
|
| Transfection | 8 | 2008 | 883 | 0.210 |
Why?
|
| Histone Deacetylases | 1 | 2005 | 86 | 0.210 |
Why?
|
| Cell Survival | 6 | 2020 | 1014 | 0.210 |
Why?
|
| Androgen Antagonists | 3 | 2018 | 157 | 0.210 |
Why?
|
| MicroRNAs | 3 | 2015 | 604 | 0.210 |
Why?
|
| Unfolded Protein Response | 2 | 2021 | 51 | 0.200 |
Why?
|
| Deoxyribonucleotides | 2 | 2023 | 8 | 0.200 |
Why?
|
| Transcription Factor AP-1 | 2 | 2000 | 68 | 0.190 |
Why?
|
| Phosphites | 1 | 2023 | 2 | 0.190 |
Why?
|
| Demethylation | 1 | 2023 | 12 | 0.190 |
Why?
|
| Methane | 1 | 2023 | 16 | 0.190 |
Why?
|
| Eukaryotic Cells | 1 | 2003 | 44 | 0.190 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 52 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 15 | 2021 | 1028 | 0.190 |
Why?
|
| History, 21st Century | 2 | 2013 | 196 | 0.190 |
Why?
|
| Rats | 21 | 2021 | 4071 | 0.190 |
Why?
|
| Bile Acids and Salts | 1 | 2003 | 78 | 0.190 |
Why?
|
| Repressor Proteins | 2 | 2005 | 448 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 16 | 1995 | 291 | 0.180 |
Why?
|
| Chrysenes | 1 | 2002 | 1 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2013 | 323 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2013 | 304 | 0.180 |
Why?
|
| Hormones | 2 | 2020 | 138 | 0.180 |
Why?
|
| Progestins | 3 | 2017 | 22 | 0.180 |
Why?
|
| Endometrial Neoplasms | 3 | 2008 | 242 | 0.170 |
Why?
|
| Protein Domains | 5 | 2021 | 169 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2022 | 159 | 0.170 |
Why?
|
| Gene Expression Profiling | 5 | 2023 | 1565 | 0.170 |
Why?
|
| Prognosis | 11 | 2018 | 4116 | 0.170 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 211 | 0.170 |
Why?
|
| Proteolysis | 2 | 2021 | 129 | 0.170 |
Why?
|
| Leukocyte Elastase | 1 | 2021 | 8 | 0.170 |
Why?
|
| Carcinogenesis | 2 | 2021 | 242 | 0.160 |
Why?
|
| Cricetinae | 11 | 2004 | 533 | 0.160 |
Why?
|
| Cytosol | 18 | 1995 | 193 | 0.160 |
Why?
|
| Response Elements | 2 | 2000 | 68 | 0.160 |
Why?
|
| Cell Membrane | 3 | 2014 | 673 | 0.160 |
Why?
|
| Genomics | 2 | 2016 | 898 | 0.160 |
Why?
|
| Epithelium | 5 | 2013 | 316 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2019 | 11 | 0.150 |
Why?
|
| Macrocyclic Compounds | 1 | 2019 | 8 | 0.150 |
Why?
|
| Cycloaddition Reaction | 1 | 2019 | 6 | 0.150 |
Why?
|
| Mutant Proteins | 2 | 2018 | 98 | 0.150 |
Why?
|
| Universities | 1 | 2020 | 166 | 0.150 |
Why?
|
| Subcellular Fractions | 2 | 2008 | 84 | 0.140 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2018 | 10 | 0.140 |
Why?
|
| Cloning, Molecular | 9 | 2008 | 581 | 0.140 |
Why?
|
| Benzopyrans | 1 | 2018 | 12 | 0.140 |
Why?
|
| Endothelium, Vascular | 3 | 2014 | 440 | 0.140 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2018 | 145 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2016 | 139 | 0.140 |
Why?
|
| Ejaculatory Ducts | 1 | 1997 | 2 | 0.130 |
Why?
|
| Megestrol Acetate | 1 | 2017 | 9 | 0.130 |
Why?
|
| Mass Spectrometry | 2 | 1995 | 191 | 0.130 |
Why?
|
| Genitalia, Male | 1 | 1997 | 24 | 0.130 |
Why?
|
| Ovarian Neoplasms | 4 | 2011 | 826 | 0.130 |
Why?
|
| Cluster Analysis | 2 | 2016 | 402 | 0.130 |
Why?
|
| Proteins | 3 | 2005 | 804 | 0.130 |
Why?
|
| Hydrogen Bonding | 2 | 2008 | 160 | 0.130 |
Why?
|
| Blotting, Western | 8 | 2014 | 780 | 0.130 |
Why?
|
| CHO Cells | 8 | 2004 | 188 | 0.130 |
Why?
|
| Base Sequence | 14 | 2012 | 2222 | 0.130 |
Why?
|
| Progesterone | 4 | 1992 | 126 | 0.130 |
Why?
|
| Cells, Cultured | 9 | 2008 | 2855 | 0.130 |
Why?
|
| Ovary | 6 | 2011 | 260 | 0.130 |
Why?
|
| Antibodies | 8 | 1998 | 349 | 0.130 |
Why?
|
| Carcinoma | 3 | 1996 | 440 | 0.130 |
Why?
|
| Metabolome | 1 | 2017 | 70 | 0.130 |
Why?
|
| Neoplasms | 3 | 2021 | 3340 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2021 | 9711 | 0.120 |
Why?
|
| Interferons | 1 | 2017 | 114 | 0.120 |
Why?
|
| Eukaryotic Initiation Factor-4A | 1 | 2016 | 4 | 0.120 |
Why?
|
| Cell Movement | 3 | 2011 | 815 | 0.120 |
Why?
|
| Communication | 1 | 2020 | 455 | 0.120 |
Why?
|
| Nucleotide Motifs | 1 | 2016 | 50 | 0.120 |
Why?
|
| Interleukin-11 | 2 | 2013 | 20 | 0.120 |
Why?
|
| Hydrocarbons | 1 | 2016 | 12 | 0.120 |
Why?
|
| Transcriptome | 2 | 2023 | 820 | 0.120 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 298 | 0.120 |
Why?
|
| Social Work | 1 | 1996 | 21 | 0.120 |
Why?
|
| Breast | 4 | 1993 | 315 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 400 | 0.120 |
Why?
|
| Nucleosomes | 1 | 2016 | 63 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 911 | 0.120 |
Why?
|
| Prolactin | 2 | 2013 | 90 | 0.120 |
Why?
|
| Psychotherapy | 1 | 1996 | 76 | 0.110 |
Why?
|
| Apoptosis | 2 | 2020 | 1752 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 5 | 2008 | 895 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 191 | 0.110 |
Why?
|
| Cultural Diversity | 1 | 1996 | 64 | 0.110 |
Why?
|
| Molecular Dynamics Simulation | 4 | 2020 | 325 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 50 | 0.110 |
Why?
|
| Estetrol | 1 | 2014 | 1 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 2 | 2008 | 512 | 0.110 |
Why?
|
| Phenotype | 5 | 2016 | 2638 | 0.110 |
Why?
|
| Protein Folding | 2 | 2008 | 291 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2016 | 257 | 0.110 |
Why?
|
| Cytoskeleton | 2 | 2013 | 200 | 0.110 |
Why?
|
| Chromatography, Affinity | 6 | 2005 | 73 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2013 | 50 | 0.100 |
Why?
|
| Autoradiography | 2 | 2008 | 51 | 0.100 |
Why?
|
| North Dakota | 1 | 2013 | 10 | 0.100 |
Why?
|
| Models, Biological | 4 | 2020 | 1807 | 0.100 |
Why?
|
| Radioligand Assay | 7 | 2007 | 32 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 321 | 0.100 |
Why?
|
| Gene Ontology | 1 | 2013 | 38 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 86 | 0.100 |
Why?
|
| Tissue Fixation | 1 | 1993 | 39 | 0.100 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 26 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2013 | 59 | 0.100 |
Why?
|
| Androgens | 1 | 2013 | 164 | 0.090 |
Why?
|
| Vimentin | 1 | 2012 | 47 | 0.090 |
Why?
|
| Allosteric Regulation | 2 | 2021 | 76 | 0.090 |
Why?
|
| Drug Design | 1 | 2013 | 135 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 1991 | 133 | 0.090 |
Why?
|
| Nuclear Receptor Coactivator 2 | 3 | 2002 | 16 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2013 | 353 | 0.090 |
Why?
|
| Prostate | 3 | 1991 | 434 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 1945 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 564 | 0.090 |
Why?
|
| Decidua | 1 | 1992 | 22 | 0.090 |
Why?
|
| Illinois | 1 | 2013 | 522 | 0.090 |
Why?
|
| Peptide Fragments | 4 | 2002 | 480 | 0.090 |
Why?
|
| Drug Interactions | 2 | 2011 | 239 | 0.090 |
Why?
|
| Pregnancy Trimester, First | 1 | 1992 | 65 | 0.090 |
Why?
|
| Menopause | 6 | 1991 | 94 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2022 | 164 | 0.090 |
Why?
|
| Male | 20 | 2018 | 47077 | 0.090 |
Why?
|
| Dimerization | 3 | 2007 | 149 | 0.090 |
Why?
|
| Immunoprecipitation | 2 | 2008 | 139 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 889 | 0.080 |
Why?
|
| RNA, Messenger | 11 | 1997 | 2063 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2006 | 1255 | 0.080 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2011 | 25 | 0.080 |
Why?
|
| Menstrual Cycle | 3 | 1988 | 84 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2020 | 110 | 0.080 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 1764 | 0.080 |
Why?
|
| Hippocampus | 3 | 2008 | 462 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2018 | 830 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 197 | 0.080 |
Why?
|
| Peptide Library | 2 | 2011 | 87 | 0.080 |
Why?
|
| Enzyme Activation | 3 | 2008 | 679 | 0.080 |
Why?
|
| Substrate Specificity | 3 | 2017 | 374 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 2658 | 0.080 |
Why?
|
| Prostatic Neoplasms | 4 | 2018 | 1836 | 0.080 |
Why?
|
| CREB-Binding Protein | 2 | 2007 | 16 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 1110 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 1999 | 234 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 582 | 0.070 |
Why?
|
| Seminiferous Epithelium | 1 | 2009 | 2 | 0.070 |
Why?
|
| Antigen-Antibody Complex | 7 | 1988 | 89 | 0.070 |
Why?
|
| Sertoli Cells | 1 | 2009 | 18 | 0.070 |
Why?
|
| Oligospermia | 1 | 2009 | 4 | 0.070 |
Why?
|
| Genitalia, Female | 2 | 1986 | 27 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2001 | 218 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2011 | 720 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 461 | 0.070 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 217 | 0.070 |
Why?
|
| Osteosarcoma | 2 | 2006 | 157 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2018 | 1527 | 0.070 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 1089 | 0.070 |
Why?
|
| Protein Conformation, alpha-Helical | 2 | 2018 | 16 | 0.070 |
Why?
|
| Testosterone | 2 | 2009 | 265 | 0.070 |
Why?
|
| Amino Acids | 4 | 2004 | 246 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 85 | 0.070 |
Why?
|
| Point Mutation | 1 | 2009 | 237 | 0.070 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2008 | 131 | 0.070 |
Why?
|
| Luteinizing Hormone | 1 | 2008 | 146 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2008 | 220 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2008 | 500 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 373 | 0.070 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 1211 | 0.070 |
Why?
|
| Boron | 1 | 2007 | 1 | 0.070 |
Why?
|
| Binding, Competitive | 8 | 1999 | 136 | 0.060 |
Why?
|
| Cattle | 8 | 1986 | 397 | 0.060 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2007 | 32 | 0.060 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2007 | 48 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 334 | 0.060 |
Why?
|
| Nitrogen | 1 | 2007 | 74 | 0.060 |
Why?
|
| Gene Library | 2 | 2005 | 125 | 0.060 |
Why?
|
| Carbon | 1 | 2007 | 99 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2008 | 479 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2018 | 529 | 0.060 |
Why?
|
| Genistein | 1 | 2006 | 16 | 0.060 |
Why?
|
| eIF-2 Kinase | 1 | 2026 | 52 | 0.060 |
Why?
|
| Phenol | 1 | 2006 | 7 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 41 | 0.060 |
Why?
|
| HeLa Cells | 3 | 2014 | 523 | 0.060 |
Why?
|
| Crystallography | 1 | 2006 | 46 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2003 | 1782 | 0.060 |
Why?
|
| Rabbits | 7 | 1988 | 581 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 1950 | 0.060 |
Why?
|
| Methionine | 1 | 2006 | 64 | 0.060 |
Why?
|
| Disease Progression | 2 | 2023 | 1610 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2006 | 100 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 53 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 83 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2008 | 280 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 280 | 0.060 |
Why?
|
| Chickens | 7 | 1992 | 195 | 0.060 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1985 | 7 | 0.060 |
Why?
|
| Middle Aged | 19 | 2009 | 29428 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 642 | 0.060 |
Why?
|
| Protein Interaction Mapping | 1 | 2005 | 79 | 0.050 |
Why?
|
| Molecular Weight | 7 | 1987 | 280 | 0.050 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2005 | 105 | 0.050 |
Why?
|
| Vitellogenins | 4 | 1998 | 10 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1985 | 30 | 0.050 |
Why?
|
| DNA, Neoplasm | 4 | 2020 | 267 | 0.050 |
Why?
|
| Weight Loss | 1 | 2006 | 245 | 0.050 |
Why?
|
| Tissue Distribution | 6 | 1993 | 290 | 0.050 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 1995 | 119 | 0.050 |
Why?
|
| Protein Engineering | 1 | 2005 | 159 | 0.050 |
Why?
|
| Tritium | 3 | 1997 | 113 | 0.050 |
Why?
|
| Adult | 17 | 2006 | 29539 | 0.050 |
Why?
|
| Aged | 15 | 2009 | 21758 | 0.050 |
Why?
|
| COS Cells | 1 | 2004 | 163 | 0.050 |
Why?
|
| Molecular Conformation | 1 | 2004 | 112 | 0.050 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 993 | 0.050 |
Why?
|
| Staining and Labeling | 4 | 1996 | 161 | 0.050 |
Why?
|
| Calcium | 1 | 2008 | 1196 | 0.050 |
Why?
|
| Genotype | 1 | 2008 | 1888 | 0.050 |
Why?
|
| Kinetics | 7 | 2017 | 1476 | 0.050 |
Why?
|
| Cross Reactions | 6 | 2001 | 115 | 0.050 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2022 | 27 | 0.050 |
Why?
|
| Luminescent Measurements | 1 | 2003 | 64 | 0.050 |
Why?
|
| Iodine Radioisotopes | 3 | 1996 | 145 | 0.050 |
Why?
|
| DNA Damage | 2 | 2013 | 399 | 0.050 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2022 | 51 | 0.050 |
Why?
|
| Genes | 3 | 1988 | 256 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 4 | 1997 | 348 | 0.050 |
Why?
|
| Ovariectomy | 2 | 2014 | 94 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2003 | 137 | 0.040 |
Why?
|
| Histocytochemistry | 4 | 1988 | 122 | 0.040 |
Why?
|
| Raloxifene Hydrochloride | 2 | 2018 | 10 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2009 | 1445 | 0.040 |
Why?
|
| Immunoglobulins | 2 | 1979 | 123 | 0.040 |
Why?
|
| Immunoassay | 6 | 1991 | 102 | 0.040 |
Why?
|
| Neurons | 2 | 2008 | 1619 | 0.040 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2021 | 3 | 0.040 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2021 | 4 | 0.040 |
Why?
|
| Receptors, Cell Surface | 4 | 1996 | 291 | 0.040 |
Why?
|
| Pancreatic Elastase | 1 | 2021 | 15 | 0.040 |
Why?
|
| Coronary Vessels | 2 | 1996 | 178 | 0.040 |
Why?
|
| Frozen Sections | 2 | 1993 | 51 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 71 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 51 | 0.040 |
Why?
|
| fas Receptor | 1 | 2021 | 73 | 0.040 |
Why?
|
| Growth Substances | 1 | 2001 | 79 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 5 | 1999 | 238 | 0.040 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2020 | 21 | 0.040 |
Why?
|
| Benzothiazoles | 1 | 2020 | 19 | 0.040 |
Why?
|
| Fluorescence | 1 | 2020 | 100 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 639 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 257 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 303 | 0.040 |
Why?
|
| Histones | 2 | 2021 | 370 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2020 | 93 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1985 | 1105 | 0.040 |
Why?
|
| United States | 1 | 2013 | 8197 | 0.040 |
Why?
|
| Species Specificity | 6 | 1988 | 690 | 0.040 |
Why?
|
| Mucoproteins | 1 | 2019 | 21 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 57 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 327 | 0.040 |
Why?
|
| Rats, Inbred Strains | 4 | 1993 | 300 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 592 | 0.040 |
Why?
|
| Stereoisomerism | 2 | 2018 | 102 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1995 | 308 | 0.040 |
Why?
|
| Oligonucleotides | 3 | 1986 | 93 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2019 | 99 | 0.040 |
Why?
|
| Chemotaxis | 1 | 1999 | 77 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 346 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 400 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 205 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2019 | 66 | 0.040 |
Why?
|
| Tissue Preservation | 3 | 1989 | 15 | 0.040 |
Why?
|
| Antibody Specificity | 3 | 2001 | 126 | 0.040 |
Why?
|
| Obesity | 1 | 2006 | 1061 | 0.040 |
Why?
|
| Methylation | 3 | 2016 | 294 | 0.040 |
Why?
|
| Thymine Nucleotides | 2 | 1975 | 6 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1605 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2003 | 467 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 184 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2018 | 59 | 0.040 |
Why?
|
| Epitopes | 4 | 1988 | 259 | 0.030 |
Why?
|
| Health Promotion | 1 | 2020 | 176 | 0.030 |
Why?
|
| Centrifugation, Density Gradient | 4 | 1985 | 93 | 0.030 |
Why?
|
| Fluorocarbons | 1 | 2018 | 64 | 0.030 |
Why?
|
| Aging | 2 | 2013 | 770 | 0.030 |
Why?
|
| Cervix Uteri | 3 | 1988 | 73 | 0.030 |
Why?
|
| Fallopian Tubes | 3 | 1988 | 49 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 174 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1998 | 273 | 0.030 |
Why?
|
| Crystallization | 1 | 1998 | 219 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2018 | 129 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2018 | 118 | 0.030 |
Why?
|
| Troleandomycin | 1 | 2017 | 3 | 0.030 |
Why?
|
| Hybrid Cells | 4 | 1987 | 68 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 5 | 0.030 |
Why?
|
| Glucuronides | 1 | 2017 | 34 | 0.030 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2017 | 11 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 1997 | 380 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2017 | 48 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 41 | 0.030 |
Why?
|
| Ketoconazole | 1 | 2017 | 23 | 0.030 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2017 | 2 | 0.030 |
Why?
|
| Microscopy, Electron | 3 | 1993 | 435 | 0.030 |
Why?
|
| STAT2 Transcription Factor | 1 | 2017 | 7 | 0.030 |
Why?
|
| Myometrium | 4 | 1992 | 62 | 0.030 |
Why?
|
| Quality of Life | 1 | 2006 | 1895 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 1994 | 2080 | 0.030 |
Why?
|
| Time Factors | 5 | 2006 | 5567 | 0.030 |
Why?
|
| Blotting, Northern | 3 | 2007 | 239 | 0.030 |
Why?
|
| Oviducts | 5 | 1987 | 6 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 7 | 1996 | 195 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 1996 | 45 | 0.030 |
Why?
|
| ErbB Receptors | 2 | 2004 | 516 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 640 | 0.030 |
Why?
|
| Steroids | 1 | 1997 | 168 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 699 | 0.030 |
Why?
|
| Egg Proteins | 1 | 1996 | 10 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 1996 | 352 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 419 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1999 | 767 | 0.030 |
Why?
|
| Linear Energy Transfer | 1 | 1996 | 5 | 0.030 |
Why?
|
| Family Therapy | 1 | 1996 | 18 | 0.030 |
Why?
|
| Protein Kinases | 2 | 1987 | 212 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 1996 | 48 | 0.030 |
Why?
|
| Pregnancy | 4 | 2009 | 3244 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2016 | 101 | 0.030 |
Why?
|
| Hexestrol | 1 | 1995 | 1 | 0.030 |
Why?
|
| Azirines | 1 | 1995 | 3 | 0.030 |
Why?
|
| Vagina | 2 | 1988 | 186 | 0.030 |
Why?
|
| Cell Fusion | 3 | 1995 | 34 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 1996 | 7389 | 0.030 |
Why?
|
| Self Concept | 1 | 1996 | 139 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 354 | 0.030 |
Why?
|
| Trypsin | 3 | 1995 | 92 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 1993 | 524 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1995 | 403 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2009 | 831 | 0.030 |
Why?
|
| Organophosphorus Compounds | 1 | 1975 | 46 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2014 | 2209 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2006 | 4025 | 0.030 |
Why?
|
| Promegestone | 3 | 1989 | 4 | 0.030 |
Why?
|
| Phosphorylation | 5 | 2004 | 1145 | 0.030 |
Why?
|
| Estrenes | 3 | 1989 | 7 | 0.030 |
Why?
|
| Isomerases | 1 | 1994 | 9 | 0.030 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 1994 | 17 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 61 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 121 | 0.030 |
Why?
|
| Endothelium | 1 | 1994 | 63 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 227 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 278 | 0.030 |
Why?
|
| Exons | 2 | 1993 | 451 | 0.030 |
Why?
|
| Genes, Reporter | 3 | 1999 | 276 | 0.020 |
Why?
|
| Progesterone Congeners | 2 | 1992 | 4 | 0.020 |
Why?
|
| Uterine Neoplasms | 2 | 1989 | 289 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1995 | 1061 | 0.020 |
Why?
|
| Pregnenediones | 2 | 1992 | 8 | 0.020 |
Why?
|
| Prospective Studies | 2 | 1994 | 4823 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2013 | 49 | 0.020 |
Why?
|
| Lymphatic Metastasis | 3 | 1991 | 520 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 1993 | 77 | 0.020 |
Why?
|
| Formaldehyde | 1 | 1993 | 52 | 0.020 |
Why?
|
| Calibration | 1 | 2013 | 110 | 0.020 |
Why?
|
| Suppression, Genetic | 1 | 2013 | 30 | 0.020 |
Why?
|
| Scintillation Counting | 2 | 1999 | 5 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 53 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1991 | 145 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 1985 | 480 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1995 | 572 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1995 | 330 | 0.020 |
Why?
|
| Drug Resistance | 2 | 1990 | 233 | 0.020 |
Why?
|
| Cell Division | 4 | 2001 | 689 | 0.020 |
Why?
|
| Sexual Behavior, Animal | 2 | 2009 | 97 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 1994 | 922 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 4 | 1995 | 126 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2013 | 285 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 301 | 0.020 |
Why?
|
| Neuroglia | 1 | 1992 | 78 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2013 | 222 | 0.020 |
Why?
|
| Epidermal Growth Factor | 2 | 1989 | 116 | 0.020 |
Why?
|
| Oligodendroglia | 1 | 1992 | 78 | 0.020 |
Why?
|
| Somatomedins | 2 | 1989 | 28 | 0.020 |
Why?
|
| Goats | 3 | 1980 | 16 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 518 | 0.020 |
Why?
|
| Protein Biosynthesis | 3 | 1989 | 393 | 0.020 |
Why?
|
| DNA Repair | 1 | 2013 | 363 | 0.020 |
Why?
|
| Receptors, Estradiol | 4 | 1984 | 5 | 0.020 |
Why?
|
| Polyunsaturated Alkamides | 1 | 1990 | 9 | 0.020 |
Why?
|
| Cadmium | 1 | 1990 | 30 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1990 | 35 | 0.020 |
Why?
|
| Metallothionein | 1 | 1990 | 12 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1991 | 299 | 0.020 |
Why?
|
| Xenopus laevis | 3 | 1998 | 140 | 0.020 |
Why?
|
| Breast Diseases | 1 | 1991 | 101 | 0.020 |
Why?
|
| Survival Rate | 1 | 1994 | 2041 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1990 | 142 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 256 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2003 | 1751 | 0.020 |
Why?
|
| Brain | 2 | 1992 | 2430 | 0.020 |
Why?
|
| Aziridines | 1 | 1989 | 10 | 0.020 |
Why?
|
| Ketones | 1 | 1989 | 15 | 0.020 |
Why?
|
| Paraffin | 1 | 1989 | 4 | 0.020 |
Why?
|
| Endometrial Hyperplasia | 1 | 1989 | 12 | 0.020 |
Why?
|
| Superovulation | 1 | 2009 | 9 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 4 | 1996 | 157 | 0.020 |
Why?
|
| Ovarian Follicle | 1 | 2009 | 65 | 0.020 |
Why?
|
| Infertility | 1 | 2009 | 36 | 0.020 |
Why?
|
| Hawaii | 1 | 2009 | 27 | 0.020 |
Why?
|
| Norpregnadienes | 1 | 1989 | 9 | 0.020 |
Why?
|
| Aromatase | 1 | 1988 | 12 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1989 | 60 | 0.020 |
Why?
|
| Cysteine | 1 | 1989 | 149 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2013 | 1147 | 0.020 |
Why?
|
| Alleles | 2 | 2009 | 1159 | 0.020 |
Why?
|
| Temperature | 2 | 1984 | 442 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1989 | 118 | 0.020 |
Why?
|
| Cricetulus | 2 | 2004 | 123 | 0.020 |
Why?
|
| Carotid Artery, Internal | 1 | 1988 | 74 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1992 | 682 | 0.020 |
Why?
|
| Osteoblasts | 1 | 1988 | 97 | 0.020 |
Why?
|
| Thymidine | 2 | 1999 | 58 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 839 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 39 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 74 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 45 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 1991 | 709 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2007 | 90 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 27 | 0.020 |
Why?
|
| Guinea Pigs | 3 | 1989 | 161 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2009 | 299 | 0.020 |
Why?
|
| Methods | 2 | 1985 | 134 | 0.020 |
Why?
|
| Aorta | 1 | 1988 | 275 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1987 | 106 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 310 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 726 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3603 | 0.020 |
Why?
|
| Oncogenes | 1 | 1987 | 102 | 0.020 |
Why?
|
| Adenine Nucleotides | 1 | 1986 | 57 | 0.020 |
Why?
|
| Rhode Island | 1 | 2006 | 11 | 0.020 |
Why?
|
| Nutritional Sciences | 1 | 2006 | 12 | 0.020 |
Why?
|
| Endopeptidases | 2 | 1998 | 114 | 0.020 |
Why?
|
| Endometriosis | 1 | 1987 | 67 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1999 | 26 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1986 | 37 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1986 | 50 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2007 | 282 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 1986 | 38 | 0.010 |
Why?
|
| Conserved Sequence | 2 | 1997 | 209 | 0.010 |
Why?
|
| Collodion | 1 | 1985 | 6 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1985 | 96 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1985 | 38 | 0.010 |
Why?
|
| Thiophenes | 1 | 1985 | 46 | 0.010 |
Why?
|
| Overweight | 1 | 2006 | 123 | 0.010 |
Why?
|
| Hydrolysis | 2 | 1995 | 145 | 0.010 |
Why?
|
| Gold | 1 | 2005 | 45 | 0.010 |
Why?
|
| Myocardium | 1 | 1988 | 578 | 0.010 |
Why?
|
| Life Style | 1 | 2006 | 193 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1985 | 33 | 0.010 |
Why?
|
| Ovulation | 1 | 1984 | 67 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1984 | 11 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Fixatives | 1 | 1984 | 13 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2004 | 24 | 0.010 |
Why?
|
| Cell Physiological Phenomena | 1 | 2004 | 24 | 0.010 |
Why?
|
| Counseling | 1 | 2006 | 191 | 0.010 |
Why?
|
| Child | 1 | 1996 | 7681 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 707 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 125 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2004 | 277 | 0.010 |
Why?
|
| Cross-Linking Reagents | 2 | 1999 | 89 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2006 | 350 | 0.010 |
Why?
|
| Guanine | 2 | 1998 | 194 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1985 | 189 | 0.010 |
Why?
|
| Solubility | 1 | 1984 | 187 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 285 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 25 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1984 | 276 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1984 | 286 | 0.010 |
Why?
|
| Exercise | 1 | 2006 | 380 | 0.010 |
Why?
|
| Stem Cells | 1 | 1985 | 396 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 417 | 0.010 |
Why?
|
| Androstane-3,17-diol | 1 | 1982 | 3 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1987 | 582 | 0.010 |
Why?
|
| Androstanols | 1 | 1982 | 12 | 0.010 |
Why?
|
| Serine Endopeptidases | 2 | 1995 | 154 | 0.010 |
Why?
|
| Liver | 1 | 1987 | 1231 | 0.010 |
Why?
|
| Hybridomas | 1 | 1982 | 61 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2555 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1982 | 219 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 139 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 3212 | 0.010 |
Why?
|
| Research | 1 | 2003 | 257 | 0.010 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2001 | 12 | 0.010 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2001 | 18 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2001 | 21 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2001 | 41 | 0.010 |
Why?
|
| Blotting, Southern | 2 | 1991 | 107 | 0.010 |
Why?
|
| Lung | 1 | 1988 | 1407 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1980 | 25 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2001 | 100 | 0.010 |
Why?
|
| Fibrocystic Breast Disease | 2 | 1991 | 12 | 0.010 |
Why?
|
| Myeloma Proteins | 1 | 1980 | 36 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1980 | 172 | 0.010 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1999 | 9 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 1999 | 12 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1982 | 461 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1999 | 54 | 0.010 |
Why?
|
| Polytetrafluoroethylene | 1 | 1999 | 72 | 0.010 |
Why?
|
| Transcription Factor TFIIB | 1 | 1999 | 2 | 0.010 |
Why?
|
| Clone Cells | 1 | 1980 | 220 | 0.010 |
Why?
|
| Titrimetry | 1 | 1999 | 14 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 1999 | 24 | 0.010 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 1999 | 14 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1980 | 153 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 102 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 1999 | 45 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 1999 | 87 | 0.010 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1999 | 27 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1999 | 139 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1999 | 77 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1980 | 263 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 85 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 890 | 0.010 |
Why?
|
| Antigens | 1 | 1980 | 225 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 98 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1999 | 127 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1999 | 153 | 0.010 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 1999 | 158 | 0.010 |
Why?
|
| Lymphoma | 1 | 1980 | 254 | 0.010 |
Why?
|
| Adenylyl Cyclases | 1 | 1999 | 105 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1999 | 132 | 0.010 |
Why?
|
| Cell Communication | 1 | 1999 | 223 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1999 | 154 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1999 | 150 | 0.010 |
Why?
|
| Mouth Floor | 1 | 1978 | 4 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1998 | 18 | 0.010 |
Why?
|
| DNA Footprinting | 1 | 1998 | 16 | 0.010 |
Why?
|
| Fibrosis | 1 | 1999 | 234 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1999 | 419 | 0.010 |
Why?
|
| Mifepristone | 2 | 1989 | 56 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1999 | 312 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1982 | 369 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1999 | 367 | 0.010 |
Why?
|
| Wound Healing | 1 | 1999 | 384 | 0.010 |
Why?
|
| Nitrogen Isotopes | 2 | 1988 | 13 | 0.010 |
Why?
|
| Genetic Vectors | 2 | 1989 | 426 | 0.010 |
Why?
|
| Deuterium | 2 | 1988 | 34 | 0.010 |
Why?
|
| Carbon Isotopes | 2 | 1988 | 59 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1996 | 47 | 0.010 |
Why?
|
| Trefoil Factor-1 | 1 | 1996 | 2 | 0.010 |
Why?
|
| Piperidines | 1 | 1997 | 172 | 0.010 |
Why?
|
| Yeasts | 1 | 1996 | 50 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1996 | 89 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 1999 | 324 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1997 | 353 | 0.010 |
Why?
|
| Thermolysin | 1 | 1995 | 9 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1995 | 24 | 0.010 |
Why?
|
| Chymotrypsin | 1 | 1995 | 29 | 0.010 |
Why?
|
| Chromatography, Paper | 1 | 1975 | 11 | 0.010 |
Why?
|
| Phosphines | 1 | 1975 | 4 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 1978 | 222 | 0.010 |
Why?
|
| Chemistry | 1 | 1975 | 46 | 0.010 |
Why?
|
| Arteries | 1 | 1996 | 171 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 1995 | 44 | 0.010 |
Why?
|
| Azides | 1 | 1975 | 12 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1975 | 65 | 0.010 |
Why?
|
| Disulfides | 1 | 1975 | 66 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1995 | 55 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2000 | 1005 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1996 | 231 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1999 | 750 | 0.010 |
Why?
|
| Postmenopause | 1 | 1995 | 109 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1996 | 312 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 1993 | 24 | 0.010 |
Why?
|
| Fetus | 1 | 1995 | 237 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1995 | 613 | 0.010 |
Why?
|
| Castration | 2 | 1984 | 32 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1995 | 418 | 0.010 |
Why?
|
| Leukemia | 1 | 1995 | 308 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1992 | 54 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1992 | 111 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1992 | 60 | 0.010 |
Why?
|
| Xenopus | 1 | 1992 | 120 | 0.010 |
Why?
|
| Deoxyribonuclease HindIII | 1 | 1991 | 4 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1991 | 28 | 0.010 |
Why?
|
| Adolescent | 1 | 1985 | 10080 | 0.010 |
Why?
|
| Adenofibroma | 1 | 1991 | 5 | 0.010 |
Why?
|
| Biopsy | 1 | 1995 | 1224 | 0.010 |
Why?
|
| Papilloma | 1 | 1991 | 23 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1991 | 54 | 0.010 |
Why?
|
| Preoptic Area | 1 | 1989 | 6 | 0.000 |
Why?
|
| Cyanogen Bromide | 1 | 1989 | 7 | 0.000 |
Why?
|
| Affinity Labels | 1 | 1989 | 9 | 0.000 |
Why?
|
| Alkylation | 1 | 1989 | 31 | 0.000 |
Why?
|
| Receptors, Calcitriol | 1 | 1991 | 130 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1985 | 10973 | 0.000 |
Why?
|
| Placenta | 1 | 1991 | 203 | 0.000 |
Why?
|
| Hypothalamus | 1 | 1989 | 82 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1993 | 479 | 0.000 |
Why?
|
| Sex Characteristics | 1 | 1992 | 351 | 0.000 |
Why?
|
| Biopsy, Needle | 1 | 1990 | 226 | 0.000 |
Why?
|
| Receptors, Purinergic | 1 | 1989 | 7 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1989 | 60 | 0.000 |
Why?
|
| Metribolone | 1 | 1988 | 6 | 0.000 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1988 | 28 | 0.000 |
Why?
|
| Procollagen | 1 | 1988 | 9 | 0.000 |
Why?
|
| Transforming Growth Factors | 1 | 1988 | 12 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1988 | 64 | 0.000 |
Why?
|
| Phenolsulfonphthalein | 1 | 1988 | 3 | 0.000 |
Why?
|
| Plasmids | 1 | 1989 | 275 | 0.000 |
Why?
|
| Leukocytes | 1 | 1989 | 212 | 0.000 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1987 | 20 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1988 | 117 | 0.000 |
Why?
|
| Metaphase | 1 | 1987 | 20 | 0.000 |
Why?
|
| Ethinyl Estradiol | 1 | 1987 | 16 | 0.000 |
Why?
|
| Oncogene Proteins v-erbA | 1 | 1987 | 1 | 0.000 |
Why?
|
| Retroviridae Proteins | 1 | 1987 | 3 | 0.000 |
Why?
|
| Phosphates | 1 | 1987 | 165 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1988 | 462 | 0.000 |
Why?
|
| Poly A | 1 | 1986 | 20 | 0.000 |
Why?
|
| Imidoesters | 1 | 1985 | 1 | 0.000 |
Why?
|
| Isotope Labeling | 1 | 1985 | 54 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1985 | 162 | 0.000 |
Why?
|
| Drug Implants | 1 | 1984 | 36 | 0.000 |
Why?
|
| Macaca fascicularis | 1 | 1984 | 111 | 0.000 |
Why?
|
| Receptors, Thyrotropin | 1 | 1984 | 48 | 0.000 |
Why?
|
| Receptors, LDL | 1 | 1984 | 54 | 0.000 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1984 | 68 | 0.000 |
Why?
|
| Myasthenia Gravis | 1 | 1984 | 85 | 0.000 |
Why?
|
| Receptors, Nicotinic | 1 | 1984 | 133 | 0.000 |
Why?
|
| Colon | 1 | 1987 | 562 | 0.000 |
Why?
|
| Cell Fractionation | 1 | 1983 | 64 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1984 | 328 | 0.000 |
Why?
|
| Hypophysectomy | 1 | 1982 | 26 | 0.000 |
Why?
|
| Adrenalectomy | 1 | 1982 | 41 | 0.000 |
Why?
|
| Prostatic Hyperplasia | 1 | 1983 | 104 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1983 | 945 | 0.000 |
Why?
|
| RNA | 1 | 1986 | 595 | 0.000 |
Why?
|
| Insulin | 1 | 1984 | 1225 | 0.000 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1978 | 100 | 0.000 |
Why?
|
| Phosphorus Compounds | 1 | 1974 | 2 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1974 | 68 | 0.000 |
Why?
|